Egg Lecithin, Lécithine, Lécithine d'œuf, Lécithine de Graine de Soya, Lécithine de Soya, Lecitina, Ovolecithin, Ovolécithine, Phospholipide de Soja, Phospholipide de Soya, Phospholipides de Soya, Soy Lecithin, Soy Phospholipid, Soy Phospholipids, Soya Bean Lecithin, Soya Lecithin, Soybean Lecithin, Vegilecithin, Vitellin, Vitelline.
Lecithin is a fat that is essential in the cells of the body. It can be found in many foods, including soybeans and egg yolks. Lecithin is taken as a medicine. It is also used in the manufacturing of medicines, foods, and cosmetics.
Lecithin is used for reducing fatty build-up in the liver and treating memory disorders such as dementia and Alzheimer's disease. It is used to improve memory in the elderly or in people who have had a head injury. It is also used for decreasing pain after surgery, treating gallbladder disease, inflammatory bowel disease (ulcerative colitis), a nerve disease called Friedreich's ataxia, nipple blebs/blisters, mania, high cholesterol, anxiety, a skin disease called eczema, Parkinson's disease, and for improving athletic performance. It is also used in people receiving peritoneal dialysis. In combination with lithium, lecithin is used for a movement disorder called tardive dyskinesia.
You will often see lecithin as a food additive. It is used to keep certain ingredients from separating out.
Lecithin is also used in preparations for intravenous (IV) or skin injections. It is used to stabilize and prevent medicines in the preparation from separating out.
You may also see lecithin as an ingredient in some eye medicines. It is used to help keep the medicine in contact with the eye's cornea.
How does it work?
Lecithin is converted into acetylcholine, a substance that transmits nerve impulses.
Possibly Effective for...
- Liver disease. Taking lecithin seems to reduce the accumulation of fat in the liver of people who are fed long-term through a needle in the vein (parenteral nutrition).
Possibly Ineffective for...
- Age-related memory impairment. Taking lecithin alone or with physostigmine does not seem to improve memory in healthy, older adults.
- Gallbladder disease. Taking lecithin does not seem to improve gallbladder disease.
Likely Ineffective for...
- Dementia related to Alzheimer's disease or other causes.
- Age-related memory impairment.
- Head injury.
Insufficient Evidence to Rate Effectiveness for...
- Athletic performance. Early research shows that taking lecithin by mouth does not improve athletic performance in trained athletes.
- A nerve disease called Friedreich's ataxia. Early research shows that lecithin does not improve performance in people with Friedreich's ataxia.
- Fatty build-up in the liver. Early research shows that lecithin might reduce the accumulation of fat in the liver of people who are fed long-term through a needle in the vein (parenteral nutrition).
- High cholesterol. Early research shows that lecithin decreases cholesterol in healthy people. However, other research shows that lecithin does not lower cholesterol levels in people with high cholesterol.
- Mania. Early research shows that taking lecithin improves symptoms of delusions, jumbled speech, and hallucinations in people with mania.
- Parkinson's disease. Early research shows that taking lecithin by mouth does not improve symptoms in people with Parkinson's disease.
- Surgery. Early research shows that taking lecithin by mouth before surgery does not reduce pain after surgery.
- Movement disorders (tardive dyskinesia). Early research shows that taking lecithin by mouth, alone or in combination with lithium, does not appear to improve symptoms in people with tardive dyskinesia when used for 2 months.
- Inflammatory bowel disease (ulcerative colitis). Early research shows that taking a supplement called Profermin (Nordisk Rebalance, Denmark) 250 mL twice daily for 8-24 weeks improves symptoms in some people with ulcerative colitis. Profermin contains fermented oats, barley malt, lecithin, and Lactobacillus plantarum 299v.
- Dry skin.
- Other conditions.
- Dementia related to Alzheimer's disease or other causes. Taking lecithin alone or with tacrine or ergoloids does not seem to improve mental abilities in people with dementia. It also doesn't seem to slow the progression of Alzheimer's disease.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Lecithin is LIKELY SAFE for most people when taken by mouth, applied to the skin, or injected intravenously (by IV) or under the skin. It can cause some side effects including diarrhea, nausea, abdominal pain, or fullness. Lecithin might also cause allergic skin reactions in people with allergies to egg or soy.
The appropriate dose of lecithin depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for lecithin. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Barbeau, A. Emerging treatments: replacement therapy with choline or lecithin in neurological diseases. Can.J.Neurol.Sci. 1978;5(1):157-160. View abstract.
Barbeau, A. Lecithin in neurologic disorders. N.Engl.J Med 7-27-1978;299(4):200-201. View abstract.
Bellelli, A., Giomini, M., Giuliani, A. M., Giustini, M., Lorenzon, I., Rusconi, V., Sezzi, M. L., Trotta, E., and Belleli, L. Antitumor effect and cardiotoxicity of a doxorubicin-lecithin association. Anticancer Res 1988;8(1):177-186. View abstract.
Benton, D. and Donohoe, R. T. The influence on cognition of the interactions between lecithin, carnitine and carbohydrate. Psychopharmacology (Berl) 2004;175(1):84-91. View abstract.
Branconnier, R. J., Dessain, E. C., Cole, J. O., and McNiff-Langille, M. E. An analysis of dose-response of plasma choline to oral lecithin. Biol.Psychiatry 1984;19(5):765-770. View abstract.
Brinkman, S. D., Pomara, N., Goodnick, P. J., Barnett, N., and Domino, E. F. A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease). J Clin Psychopharmacol. 1982;2(4):281-285. View abstract.
Caine, E. D. Cholinomimetic treatment fails to improve memory disorders. N.Engl.J Med 9-4-1980;303(10):585-586. View abstract.
Canter, N. L., Hallett, M., and Growdon, J. H. Lecithin does not affect EEG spectral analysis or P300 in Alzheimer disease. Neurology 1982;32(11):1260-1266. View abstract.
Chuaqui, P. and Levy, R. Fluctuations of free choline levels in plasma of Alzheimer patients receiving lecithin: preliminary observations. Br.J.Psychiatry 1982;140:464-469. View abstract.
Crapper McLachlan, D. R., Dalton, A. J., Kruck, T. P., Bell, M. Y., Smith, W. L., Kalow, W., and Andrews, D. F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 6-1-1991;337(8753):1304-1308. View abstract.
Davidson, M., Mohs, R. C., Hollander, E., Zemishlany, Z., Powchik, P., Ryan, T., and Davis, K. L. Lecithin and piracetam in Alzheimer's disease. Biol.Psychiatry 1987;22(1):112-114. View abstract.
Duffy, F. H., McAnulty, G., Albert, M., Durwen, H., and Weintraub, S. Lecithin: absence of neurophysiologic effect in Alzheimer's disease by EEG topography. Neurology 1987;37(6):1015-1019. View abstract.
Dysken, M. W., Fovall, P., Harris, C. M., Davis, J. M., and Noronha, A. Lecithin administration in Alzheimer dementia. Neurology 1982;32(10):1203-1204. View abstract.
Foster, N. L., Petersen, R. C., Gracon, S. I., and Lewis, K. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group. Dementia 1996;7(5):260-266. View abstract.
Gauthier, S., Bouchard, R., Bacher, Y., Bailey, P., Bergman, H., Carrier, L., Charbonneau, R., Clarfield, M., Collier, B., Dastoor, D., and . Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease. Can.J Neurol.Sci 1989;16(4 Suppl):543-546. View abstract.
Gauthier, S., Bouchard, R., Lamontagne, A., Bailey, P., Bergman, H., Ratner, J., Tesfaye, Y., Saint-Martin, M., Bacher, Y., Carrier, L., and . Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl.J Med 5-3-1990;322(18):1272-1276. View abstract.
Gelenberg, A. J., Doller-Wojcik, J. C., and Growdon, J. H. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am J Psychiatry 1979;136(6):772-776. View abstract.
Growdon, J. H., Wheeler, S., and Graham, H. N. Plasma choline responses to lecithin-enriched soup. Psychopharmacol.Bull 1984;20(3):603-606. View abstract.
Hallett, M., Canter, N., and Growdon, J. Neurophysiologic Parameters in Alzheimer Disease: Effect of Lecithin. Neurology 1982;32(2):a126.
Halliday, H. L., McClure, G., Reid, M. M., Lappin, T. R., Meban, C., and Thomas, P. S. Controlled trial of artificial surfactant to prevent respiratory distress syndrome. Lancet 3-3-1984;1(8375):476-478. View abstract.
Holford, N. H. and Peace, K. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol 1994;47(1):17-23. View abstract.
Jackson, I. V., Nuttall, E. A., Ibe, I. O., and Perez-Cruet, J. Treatment of tardive dyskinesia with lecithin. Am J Psychiatry 1979;136(11):1458-1460. View abstract.
Kaye, W. H., Sitaram, N., Weingartner, H., Ebert, M. H., Smallberg, S., and Gillin, J. C. Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment. Biol.Psychiatry 1982;17(2):275-280. View abstract.
Kushnir, S. L., Ratner, J. T., and Gregoire, P. A. Multiple nutrients in the treatment of Alzheimer's disease. J Am Geriatr.Soc 1987;35(5):476-477. View abstract.
Lampe, T. H., Norris, J., Risse, S. C., Owen-Williams, E., and Keenan, T. Therapeutic Potential of Thyrotropin-Releasing Hormone (TRH) and Lecithin Co-administration in Alzheimer's Disease. Neurobiology of Aging 1990;11:346.
Levin, H. S. and Peters, B. H. Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease. Ann.Neurol. 1984;15(2):210. View abstract.
Levy, R., Little, A., Chuaqui, P., and Reith, M. Early results from double-blind, placebo controlled trial of high dose phosphatidylcholine in Alzheimer's disease. Lancet 4-30-1983;1(8331):987-988. View abstract.
Lieber, C. S., DeCarli, L. M., Mak, K. M., Kim, C. I., and Leo, M. A. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 1990;12(6):1390-1398. View abstract.
McLachlan, D. R., Smith, W. L., and Kruck, T. P. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther.Drug Monit. 1993;15(6):602-607. View abstract.
Melancon, S. B., Dallaire, L., Potier, M., Vanasse, M., Marois, P., Geoffroy, G., and Barbeau, A. Oral lecithin and linoleic acid in Friedreich's ataxia: I. Design of the study, material and methods. Can.J Neurol.Sci 1982;9(2):151-154. View abstract.
Nair, M. P., Kudchodkar, B. J., Pritchard, P. H., and Lacko, A. G. Purification of recombinant lecithin: cholesterol acyltransferase. Protein Expr.Purif. 1997;10(1):38-41. View abstract.
Pentland, B., Martyn, C. N., Steer, C. R., and Christie, J. E. Lecithin treatment in Friedreich's ataxia. Br Med J (Clin Res Ed) 4-11-1981;282(6271):1197-1198. View abstract.
Perez-Cruet, J., Menendez, I., Alvarez-Ghersi, J., Falcon, J. R., Valderrabano, O., Castro-Urrutia, E. C., Ifarraguerri, C., and Perez, L. L. Double-blind study of lecithin in the treatment of persistent tardive dyskinesia. Bol.Asoc.Med P.R. 1981;73(11):531-537. View abstract.
Perryman, K. M. and Fitten, L. J. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life Sci 1993;53(6):479-486. View abstract.
Perryman, K. M. and Fitten, L. J. Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol. 1991;4(3):127-133. View abstract.
Peters, B. H. and Levin, H. S. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol. 1979;6(3):219-221. View abstract.
Sannita, W. G., Balestra, V., Rosadini, G., Salama, M., and Timitilli, C. Quantitative EEG and neuropsychological effects of piracetam and of the association piracetam-lecithin in healthy volunteers. Neuropsychobiology 1985;14(4):203-209. View abstract.
Smith, R. C., Vroulis, G., Johnson, R., and Morgan, R. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacol.Bull. 1984;20(3):542-545. View abstract.
Sorgatz, H. [Effect of lecithin on health status and concentration. Placebo-controlled double-blind study in healthy probands]. Fortschr Med 4-10-1988;106(11):233-236. View abstract.
Stoll, A. L., Sachs, G. S., Cohen, B. M., Lafer, B., Christensen, J. D., and Renshaw, P. F. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol.Psychiatry 9-1-1996;40(5):382-388. View abstract.
Thal, L. J., Fuld, P. A., Masur, D. M., and Sharpless, N. S. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol. 1983;13(5):491-496. View abstract.
Thal, L. J., Masur, D. M., Sharpless, N. S., Fuld, P. A., and Davies, P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog.Neuropsychopharmacol.Biol.Psychiatry 1986;10(3-5):627-636. View abstract.
Tudorache, B., Lupulescu, R., Dutan, I., and Sarbulescu, A. Assessment of various psychopharmacological combinations in the treatment of presenile and senile primary degenerative dementia. Rom.J Neurol.Psychiatry 1990;28(4):277-294. View abstract.
Tuzhilin, S. A., Dreiling, D. A., Narodetskaja, R. V., and Lukash, L. K. The treatment of patients with gallstones by lecithin. Am J Gastroenterol. 1976;65(3):231-235. View abstract.
Uney, J. B., Jones, G. M., Rebeiro, A., and Levy, R. The effect of long-term high dose lecithin on erythrocyte choline transport in Alzheimer patients. Biol.Psychiatry 3-15-1992;31(6):630-633. View abstract.
Vida, S., Gauthier, L., and Gauthier, S. Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood. Can.J Psychiatry 1989;34(3):165-170. View abstract.
Vinarova, E. and Vinar, O. Lecithin in a Psychiatric Out-patient Clinic. Activ nerv sup (Prana) 1987;29(3):219-221.
Volz, H. P., Hehnke, U., and Hauke, W. [Improvement in quality of life in the elderly. Results of a placebo-controlled study on the efficacy and tolerability of lecithin fluid in patients with impaired cognitive functions]. MMW Fortschr Med 12-9-2004;146(Suppl 3-4):99-106. View abstract.
von Allworden, H. N., Horn, S., Kahl, J., and Feldheim, W. The influence of lecithin on plasma choline concentrations in triathletes and adolescent runners during exercise. Eur.J.Appl.Physiol Occup.Physiol 1993;67(1):87-91. View abstract.
Vroulis, G. A., Smith, R. C., Brinkman, S., Schoolar, J., and Gordon, J. The effects of lecithin on memory in patients with senile dementia of the Alzheimer's type [proceedings]. Psychopharmacol Bull 1981;17(1):127-128. View abstract.
Vroulis, G., Smith, R. C., Schoolar, J. C., Dahlen, G., Katz, E., and Misra, C. H. Reduction of cholesterol risk factors by lecithin in patients with Alzheimer's disease. Am J Psychiatry 1982;139(12):1633-1634. View abstract.
Weintraub, S., Mesulan, M. M., Auty, R., Baratz, R., Cholakos, B. N., Kapust, L., Ransil, B., Tellers, J. G., Albert, M. S., LoCastro, S., and Moss, M. Lecithin in the treatment of Alzheimer's disease. Arch Neurol. 1983;40(8):527-528. View abstract.
Wurtman, R. J., Hirsch, M. J., and Growdon, J. H. Lecithin consumption raises serum-free-choline levels. Lancet 7-9-1977;2(8028):68-69. View abstract.
Zhang, A. Q., Mitchell, S. C., and Smith, R. L. Dietary precursors of trimethylamine in man: a pilot study. Food Chem.Toxicol. 1999;37(5):515-520. View abstract.
Andrioli G, Carletto A, Guarini P, et al. Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion. Thromb Haemost 1999;82:1522-7. View abstract.
Brinkman SD, Pomara N, Goodnick PJ, et al. A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease). J Clin Psychopharmacol 1982;2:281-5.
Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol 1982;37:4-9. View abstract.
Buchman AL, Awal M, Jenden D, et al. The effect of lecithin supplementation on plasma choline concentrations during a marathon. J Am Coll Nutr 2000;19:768-70. View abstract.
Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363-70. View abstract.
Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. BMJ 1990;300:495-9. View abstract.
Cohen BM, Lipinski JF, Altesman RI. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry 1982;139:1162-4. View abstract.
Conte A, Ronca G, Petrini M, et al. Effect of lecithin on epicutaneous absorption of diclofenac epolamine. Drugs Exp Clin Res 2002;28:249-55. View abstract.
Di Prospero NA, Sumner CJ, Penzak SR, et al. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 2007;64:803-8. View abstract.
Domino EF, May WW, Demetriou S, et al. Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy. Biol Psychiatry 1985;20:1189-96. View abstract.
Drachman DA, Glosser G, Fleming P, et al. Memory decline in the aged: treatment with lecithin and physostigmine. Neurology 1982;32:944-50. View abstract.
Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
Etienne P, Dastoor D, Gauthier S, et al. Alzheimer disease: lack of effect of lecithin treatment for 3 months. Neurol 1981;31:1552-4. View abstract.
Evans M, Njike VY, Hoxley M, et al. Effect of soy isoflavone protein and soy lecithin on endothelial function in healthy postmenopausal women. Menopause 2007;14:141-9. View abstract.
Facts and Comparisons, loose leaf edition. St. Louis, MO: Wolters Kluwer Co., 1999.
Fioravanti A, Cicero MR, Nerucci F, et al. Double-blind controlled clinical study of the efficacy and tolerability of diclofenac-N-(2-hydroxyethyl)-pyrrolidine lecithin gel compared with diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel in patients with peri and extraarticular inflammatory diseases. Drugs Exp Clin Res 1999;25:235-40. View abstract.
Fisman M, Merskey H, Helmes E, et al. Double blind study of lecithin in patients with Alzheimer's disease. Can.J Psychiatry 1981;26:426-28. View abstract.
Fitten LJ, Perryman KM, Gross PL, et al. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 1990;147:239-42. View abstract.
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: http://books.nap.edu/books/0309065542/html/.
Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149-53. View abstract.
Goldberg AC, Ostlund RE, Bateman JH, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs.Am J Cardiol. 2-1-2006;97:376-79. View abstract.
Gremaud G, Dalan E, Piguet C, et al. Effects of non-esterified stanols in a liquid emulsion on cholesterol absorption and synthesis in hypercholesterolemic men. Eur J Nutr 2002;41:54-60. View abstract.
Growdon JH, Corkin S, Huff FJ, et al. Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 1986;7:269-76. View abstract.
Guan R, Ho KY, Kang JY, et al. The effect of polyunsaturated phosphatidyl choline in the treatment of acute viral hepatitis. Aliment Pharmacol Ther 1995;9:699-703. View abstract.
Harris CM, Dysken MW, Fovall P, Davis JM. Effect of lecithin on memory in normal adults. Am J Psychiatry 1983;140:1010-2. View abstract.
Hebel SK, ed. Drug Facts and Comparisons. 52nd ed. St. Louis: Facts and Comparisons, 1998.
Hellhammer J, Fries E, Buss C, et al. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. Stress. 2004;7:119-26. View abstract.
Heyman A, Schmechel D, Wilkinson W, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease. J Neural Transm Suppl 1987;24:279-86. View abstract.
Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2000;4:CD001015. View abstract.
Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2003;(3):CD001015. View abstract.
Holan KR, Holzbach RT, Hsieh JY, et al. Effect of oral administration of essential phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis. Digestion 1979;19:251-8. View abstract.
Jenike MA, Albert MS, Heller H, et al. Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. J Clin Psychiatry 1986;47:249-51. View abstract.
Jenkins PJ, Portmann BP, Eddleston AL, Williams R. Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982;2:77-81. View abstract.
Kapen S, Fleming PD, Drachman DA. Cholinergic enhancement and REM sleep latency in the aged: lecithin does not reproduce physostigmine effect. Neurology 1986;36:1079-83. View abstract.
Kraft JN, Lynde CW. Moisturizers: what they are and a practical approach to product selection. Skin Ther Lett 2005;10(5):1-8.
Krag A, Israelsen H, von Ryberg B, et al. Safety and efficacy of Profermin® to induce remission in ulcerative colitis. World J Gastroenterol 2012;18(15):1773-80.View abstract.
Krag A, Munkholm P, Israelsen H, von Ryberg B, Andersen KK, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis--a randomized controlled trial. Inflamm Bowel Dis. 2013;19(12):2584-92. View abstract.
Ladd SL, Sommer SA, LaBerge S, Toscano W. Effect of phosphatidylcholine on explicit memory. Clin Neuropharmacol 1993;16:540-9. View abstract.
Levin HS, Peters BH, Kalisky Z, et al. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. Cent.Nerv.Syst.Trauma 1986;3:333-42. View abstract.
Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:736-42. View abstract.
Mahler P, Mahler F, Duruz H, et al. Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions. Drugs Exp Clin Res 2003;29:45-52. View abstract.
Maltby N, Broe GA, Creasey H, et al. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double-blind trial. BMJ 1994;308:879-83. View abstract.
Melancon SB, Vanasse M, Geoffroy G, et al. Oral lecithin and linoleic acid in Friedreich's ataxia: II. Clinical results. Can.J Neurol.Sci 1982;9:155-64. View abstract.
Oosthuizen W, Vorster HH, Vermaak WJ, et al. Lecithin has no effect on serum lipoprotein, plasma fibrinogen and macro molecular protein complex levels in hyperlipidaemic men in a double-blind controlled study. Eur J Clin Nutr 1998;52:419-24. View abstract.
Ostlund RE Jr, Spilburg CA, Stenson WF. Sitostanol administered in lecithin micelles potently reduces cholesterol absorption in humans. Am J Clin Nutr 1999;70:826-31. View abstract.
Palm M, Moneret-Vautrin DA, Kanny G, et al. Food allergy to egg and soy lecithins. Allergy 1999;54:1116-7. View abstract.
Pomara N, Domino EF, Yoon H, et al. Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease. J Clin Psychiatry 1983;44:293-5. View abstract.
Sidhu N, Davies S, Nadarajah A, et al. Oral choline supplementation for postoperative pain. Br J Anaesth 2013;111(2):249-55. View abstract .
Simons LA, Hickie JB, Ruys J. Treatment of hypercholesterolaemia with oral lecithin. Aust N Z J Med 1977;7:262-6. View abstract.
Sourkes TL. The discovery of lecithin, the first phospholipid. Bull Hist Chem. 2004;29(1):9-15.
Spilburg CA, Goldberg AC, McGill JB, et al. Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. J Am Diet Assoc 2003;103:577-81. View abstract.
Tweedy JR and Garcia CA. Lecithin treatment of cognitively impaired Parkinson's patients. Eur J Clin Invest 1982;12:87-90. View abstract.
Volavka J, O'Donnell J, Muragali R,et al. Lithium and lecithin in tardive dyskinesia: an update. Psychiatry Res 1986;19:101-4. View abstract.
Wade A, Weller PJ, eds. Handbook of Pharmaceutical Excipients. 2nd ed. Washington, DC: Am Pharmaceutical Assn, 1994.
Wu Y, Wang T. Soybean lecithin fractionation and functionality. JAOCS 2003;80(4):319-326.